- When independently validated proof of performance is required
- Public evidence for Remedy’s outcomes is limited (few independent reviews, minimal public case studies). If procurement requires broad third-party validation or extensive enterprise references, Remedy may be too early-stage.
- When publicly available compliance documentation is required
- The vendor asserts HIPAA compliance but does not publish SOC 2 / ISO certification documentation or detailed security controls in public sources.
- When transparent, self-serve pricing is required
- Remedy uses a demo-led sales approach and does not publish standard pricing tiers; organizations needing predictable, self-serve monthly pricing may find this approach a mismatch.
- When broad omnichannel engagement is required beyond voice
- Organizations that require integrated SMS, web chat, email outreach, and portal integration as a single vendor capability may prefer platforms with a documented omnichannel feature set.
- When procurement requires an established, long-tenured vendor
- Large enterprises may prefer vendors with a longer track record, published SLAs, and extensive referenceable deployments.
- Current limitations acknowledged by the vendor
- The vendor does not publish a consolidated list of known issues in public documentation.
- Roadmap items
- Not publicly documented.
- Scale limitations
- As an early-stage company with a very small public team listing, buyers should assume that scaling processes, support coverage, and enterprise operations may be maturing.
- Security or compliance gaps
- No public SOC 2 / ISO documentation; details on call retention, transcript storage, and subprocessors are not published.
- API limitations or integration constraints
- The vendor states PMS integrations are supported but does not publish a supported-PMS list or detailed API/integration depth.